Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RVMD Revolution Medicines, Inc.

Pre-Mkt 06-24 07:42:16 EDT

169.51

+3.70

+2.23%

盘前171.10

+1.59+0.94%

07:40 EDT

High171.25	Low163.05	Vol3.12M
Open163.30	D1 Closing165.81	Amplitude4.95%
Mkt Cap36.04B	Tradable Cap32.04B	Total Shares212.59M
T/O528.57M	T/O Rate1.65%	Tradable Shares189.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RVMD","market":"US","secType":"STK","nameCN":"Revolution Medicines, Inc.","latestPrice":169.51,"timestamp":1782244800000,"preClose":165.81,"halted":0,"volume":3124242,"hourTrading":{"tag":"盘前","latestPrice":171.1,"preClose":169.51,"latestTime":"07:40 EDT","volume":569,"amount":97202.30414000001,"timestamp":1782301207202,"change":1.59,"changeRate":0.00938,"amplitude":0.017698},"delay":0,"changeRate":0.022314697545383202,"floatShares":189000000,"shares":212592561,"eps":-7.121384,"marketStatus":"Pre-Mkt","change":3.7,"latestTime":"06-24 07:42:16 EDT","open":163.3,"high":171.25,"low":163.05,"amount":528568571.80116,"amplitude":0.049454,"askPrice":172,"askSize":50,"bidPrice":170,"bidSize":149,"shortable":3,"etf":0,"ttmEps":-7.121384,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1782307800000},"marketStatusCode":1,"adr":0,"listingDate":1581570000000,"exchange":"NASDAQ","adjPreClose":169.51,"preHourTrading":{"tag":"盘前","latestPrice":171.1,"preClose":169.51,"latestTime":"07:40 EDT","volume":569,"amount":97202.30414000001,"timestamp":1782301207202,"change":1.59,"changeRate":0.00938,"amplitude":0.017698},"postHourTrading":{"tag":"盘后","latestPrice":172.0405,"preClose":169.51,"latestTime":"19:53 EDT","volume":80481,"amount":13643609.4529,"timestamp":1782258827803,"change":2.5305,"changeRate":0.014928,"amplitude":0.017226},"volumeRatio":1.0615817171784603,"impliedVol":0.49,"impliedVolPercentile":0.304},"requestUrl":"/m/hq/s/RVMD/tweets","defaultTab":"tweets","newsList":[{"id":"2645230858","title":"Revolution Medicines begins treating patients in RASolute 305 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2645230858","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645230858?lang=en_us&edition=fundamental","pubTime":"2026-06-24 00:46","pubTimestamp":1782233208,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) announced that it has begun treating patients in RASolute 305, a global, randomized Phase 3 clinical trial evaluating z...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-begins-treating-patients-in-rasolute-305-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-begins-treating-patients-in-rasolute-305-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0320765992.SGD","IE00BJT1NW94.SGD","RVMD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE00B4R5TH58.HKD","BK4139","LU0889565916.HKD","IE0009355771.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645812834","title":"Analysts Are Bullish on These Healthcare Stocks: Revolution Medicines (RVMD), Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645812834","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645812834?lang=en_us&edition=fundamental","pubTime":"2026-06-23 21:21","pubTimestamp":1782220869,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Praxis Precision Med...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-revolution-medicines-rvmd-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-revolution-medicines-rvmd-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IE00BJT1NW94.SGD","IE0002141913.USD","LU0889565916.HKD","RVMD","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU0109394709.USD","LU0320765992.SGD","IE00B2B36J28.USD","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645280835","title":"Revolution Medicines starts Phase 3 RASolute 305 trial of zoldonrasib plus chemotherapy in first-line metastatic RAS G12D pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2645280835","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645280835?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:02","pubTimestamp":1782216171,"startTime":"0","endTime":"0","summary":"Revolution Medicines starts Phase 3 RASolute 305 trial of zoldonrasib plus chemotherapy in first-line metastatic RAS G12D pancreatic cancer. Revolution Medicines began treating patients in RASolute 305, a global Phase 3 trial of zoldonrasib with chemotherapy in first-line metastatic RAS G12D pancreatic cancer.No new trial results were presented; the study will read out progression-free survival and overall survival outcomes in the future.The trial tests whether adding zoldonrasib can improve disease control and survival versus chemotherapy alone, with safety and patient-reported outcomes tracked.The start follows earlier daraxonrasib data reported in second-line metastatic pancreatic cancer that showed improved outcomes versus standard chemotherapy.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL9lKRs7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4588","SG9999014013.SGD","IE00BN0W2T93.GBP","BK4139","IE00B2B36J28.USD","SG9999014005.SGD","LU0109394709.USD","RVMD","IE00BKPKM429.USD","BK4585","IE00BGHQF748.EUR","IE0009355771.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","SG9999014021.USD","LU2210149790.SGD","IE00BJT1NW94.SGD","NDAQ","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00B64PRP62.GBP","LU2095319765.USD","LU0314104364.USD","LU2210150020.SGD","IE00BFTCPJ56.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","LU0320765992.SGD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645083599","title":"Revolution Medicines Begins Treating Patients in Rasolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination With Chemotherapy as a First Line Treatment for Patients With Ras G12d Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2645083599","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645083599?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:00","pubTimestamp":1782216000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA74SHBM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","IE0002141913.USD","IE00B2B36J28.USD","LU0320765992.SGD","LU0889565916.HKD","IE0009355771.USD","LU0109394709.USD","BK4139","RVMD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645076335","title":"Revolution Medicines' PDAC Revenue Could Rise Up to 40% on Positive Doublet Data, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2645076335","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645076335?lang=en_us&edition=fundamental","pubTime":"2026-06-22 23:37","pubTimestamp":1782142633,"startTime":"0","endTime":"0","summary":"Revolution Medicines'  pancreatic cancer revenue could increase by up to 20% to 40% if positive data emerge from its zoldonrasib and daraxonrasib combination study in metastatic pancreatic ductal adenocarcinoma, UBS Securities said.The company is set to present new safety and efficacy data from its study evaluating zoldonrasib in combination with daraxonrasib in patients with 2L+ KRAS G12D metastatic pancreatic ductal adenocarcinoma, analysts said in a Sunday research note.UBS said it is looking for response rates above 40% for the doublet therapy in the second-line setting as an all-oral regimen.Analysts said they are also looking for updates on the filing of daraxonrasib in 2L PDAC and expect the drug to be approved and launched quickly based on positive commentary from the Food and Drug Administration.UBS has a buy rating on the stock and a $175 price target.Price: 163.98, Change: +0.99, Percent Change: +0.61","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645602415","title":"Revolution Medicines R&D chief Steve Kelsey to step down as senior adviser July 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2645602415","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645602415?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:03","pubTimestamp":1782129782,"startTime":"0","endTime":"0","summary":"Revolution Medicines named Steve Kelsey senior advisor to the CEO effective July 1, 2026, from president of research and development.Kelsey plans to retire January 4, 2027; the company expects to appoint him to the board at that time.R&D leadership shifts July 1, 2026; Chief Development Officer Alan Sandler continues to lead development.Chief Scientific Officer Jan Smith will oversee research under the new structure.Xiaolin Wang becomes executive vice president, integrated portfolio strategy and management, adding oversight of pharmaceutical development, manufacturing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL6cLlFT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00BJT1NW94.SGD","IE00BN0W2V16.EUR","LU2095319765.USD","IE00BN0W2W23.USD","IE00BFTCPJ56.SGD","SG9999014021.USD","BK4112","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014005.SGD","LU2210150020.SGD","LU0889565916.HKD","IE00B64PRP62.GBP","BK4585","BK4588","LU0320765992.SGD","IE00BN0W2T93.GBP","LU0109394709.USD","IE0002141913.USD","RVMD","IE00BJJMRZ35.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","IE0009355771.USD","SG9999014013.SGD","IE00B4R5TH58.HKD","SG9999014039.USD","IE00B2B36J28.USD","BK4139","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645918024","title":"Revolution Medicines shareholders ratify PwC as auditor for fiscal 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2645918024","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645918024?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:02","pubTimestamp":1782129752,"startTime":"0","endTime":"0","summary":"Revolution Medicines held its annual shareholder meeting on June 18, 2026.Shareholders backed the selection of two directors to serve terms running to the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL5CwrD3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","BK4139","LU0109394709.USD","RVMD","IE00BJT1NW94.SGD","LU0889565916.HKD","IE0002141913.USD","IE0009355771.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645024555","title":"Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.d.","url":"https://stock-news.laohu8.com/highlight/detail?id=2645024555","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645024555?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:00","pubTimestamp":1782129605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA9HYKD4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BFTCPJ56.SGD","LU0889565916.HKD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU0109394709.USD","LU0320765992.SGD","BK4139","RVMD","IE0002141913.USD","IE0009355771.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645094981","title":"MEDIA-Cancer drugmaker Revolution Medicines says sale not a priority - FT","url":"https://stock-news.laohu8.com/highlight/detail?id=2645094981","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645094981?lang=en_us&edition=fundamental","pubTime":"2026-06-21 12:07","pubTimestamp":1782014878,"startTime":"0","endTime":"0","summary":"MEDIA-Cancer drugmaker Revolution Medicines says sale not a priority - FT-- Source link: https://tinyurl.com/3fe4zppp-- Note: Reuters has not verified this story and does not vouch for its accuracy ((globalnewsmonitoring@thomsonreuters.com))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260621:nL4N42T005:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","BK4139","LU0109394709.USD","RVMD","IE00BJT1NW94.SGD","LU0889565916.HKD","IE0002141913.USD","IE0009355771.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644720974","title":"Revolution Medicines COO Margaret Horn disposes of 93,575 common shares worth $14.99 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2644720974","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644720974?lang=en_us&edition=fundamental","pubTime":"2026-06-18 07:52","pubTimestamp":1781740341,"startTime":"0","endTime":"0","summary":"Revolution Medicines COO Margaret A. Horn reported stock option exercises, converting 90,000 options into common shares on June 15-17.Horn sold 90,000 shares on June 15-17 at weighted average prices of USD 160.17 and USD 160.12.Directly held common shares totaled 154,647 following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDLbBVVwn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines COO Margaret Horn disposes of 93,575 common shares worth $14.99 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0109394709.USD","BK4139","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0009355771.USD","IE0002141913.USD","RVMD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643378552","title":"Revolution Medicines COO Margaret Horn disposes of 10,000 common shares worth $1.48 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2643378552","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643378552?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:07","pubTimestamp":1781554027,"startTime":"0","endTime":"0","summary":"Revolution Medicines COO Margaret A. Horn reported option exercises that added 10,000 common shares on June 11, 2026.She sold 10,000 shares the same day at weighted-average prices ranging from $144.28 to $150.17.Her direct common stock holdings ended at 158,222 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL7mqsvG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines COO Margaret Horn disposes of 10,000 common shares worth $1.48 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE0002141913.USD","IE00BJT1NW94.SGD","LU0320765992.SGD","LU0889565916.HKD","BK4139","RVMD","LU0109394709.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642872420","title":"Revolution Medicines Is Maintained at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2642872420","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642872420?lang=en_us&edition=fundamental","pubTime":"2026-06-11 00:12","pubTimestamp":1781107920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 10, 2026 12:12 ET (16:12 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122519322","title":"Movement Alert｜Revolution Medicines Falls 5.21% in Regular Trading, Trading at $142.305","url":"https://stock-news.laohu8.com/highlight/detail?id=1122519322","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122519322?lang=en_us&edition=fundamental","pubTime":"2026-06-10 23:24","pubTimestamp":1781105041,"startTime":"0","endTime":"0","summary":"On June 10, Revolution Medicines fell 5.21% in regular trading, trading at $142.305 USD/share, with trading volume of $129 million.Within the Biotechnology sector where Revolution Medicines belongs,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642425695","title":"BUZZ-Tango Therapeutics rises premarket after upsized $600 mln equity raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2642425695","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642425695?lang=en_us&edition=fundamental","pubTime":"2026-06-10 20:05","pubTimestamp":1781093148,"startTime":"0","endTime":"0","summary":"BUZZ-Tango Therapeutics rises premarket after upsized $600 mln equity raise** Shares of Tango Therapeutics TNGX.O up 1% at $31.87 in premarket trading Weds after upsized $600 mln follow-on priced** Biotech firm late Tues sold ~18.2 mln shares and pre-funded warrants to buy ~1.8 mln shares at $30, a 4.9% discount to last sale** On Mon, TNGX stock soared 53% after co's experimental pancreatic cancer drug vopimetostat, in combination with Revolution Medicines' RVMD.O daraxonrasib, showed strong early results in a small study** Subsequently, TNGX late Mon launched $500 mln stock offering** Co intends to use net offering proceeds for general purposes, including R&D, expenses for pivotal trial and preparation for potential commercialization of one or more of its product candidates, among other purposes, per the prospectus** JP Morgan, Leerink, Cantor Fitzgerald and Stifel joint bookrunners** Boston, Massachusetts-based TNGX has ~144.6 mln shares outstanding** TNGX stock finished up 2% on Tue","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nL6N42I0RZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1551013425.SGD","LU1668664300.SGD","BK4533","LU0149725797.USD","RVMD","LU2592432038.USD","LU1894683264.USD","LU1629891620.HKD","LU2505996681.GBP","IE00BN8TJ469.HKD","IE000M9KFDE8.USD","LU0211326839.USD","LU1496350502.SGD","LU2023250330.USD","LU0320765646.SGD","LU0964807845.USD","LU2023250843.SGD","LU0211331839.USD","LU0417517546.SGD","LU0006306889.USD","LU0265550359.USD","IE00BJLML261.HKD","LU0859254822.USD","LU0215105999.USD","IE00B775SV38.USD","LU2552382215.SGD","TNGX","LU1720051108.HKD","JPO","LU0868494617.USD","LU2264538146.SGD","LU0256863902.USD","LU2756315664.SGD","BK4566","LU0820562030.AUD","JPMO","BK4504","LU0070302665.USD","LU0868494708.USD","LU0496365809.HKD","LU1720051017.SGD","LU0882574139.USD","IE00BKDWB100.SGD","LU0320765992.SGD","IE00BZ1G4Q59.USD","LU1551013342.USD","IE00BFXG1179.USD","JPX","LU2505996509.AUD","LU0048584097.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642462876","title":"Revolution Medicines Earns Buy Rating on Strong PDAC Execution, First-Mover Advantage, and Daraxonrasib-Driven Growth Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2642462876","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642462876?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:16","pubTimestamp":1781003779,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Brian Cheng has maintained their bullish stance on RVMD stock, giving a Buy rating yesterday. Brian Cheng has given his Buy rat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/revolution-medicines-earns-buy-rating-on-strong-pdac-execution-first-mover-advantage-and-daraxonrasib-driven-growth-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/revolution-medicines-earns-buy-rating-on-strong-pdac-execution-first-mover-advantage-and-daraxonrasib-driven-growth-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642546480","title":"BUZZ-IDEAYA Biosciences drops on $300 mln equity raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2642546480","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642546480?lang=en_us&edition=fundamental","pubTime":"2026-06-09 18:51","pubTimestamp":1781002275,"startTime":"0","endTime":"0","summary":"BUZZ-IDEAYA Biosciences drops on $300 mln equity raise** IDEAYA Biosciences' IDYA.O shares down 9.8% before the bell on Tues to $28.40 after $300 mln overnight follow-on priced** IDYA late Mon sold ~5","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nL6N42H0OU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242649171.HKD","LU0417517546.SGD","LU1145028129.USD","BK4504","JPO","JPX","LU1244550577.SGD","LU0234572021.USD","LU2054465674.USD","LU1366192091.USD","SG9999002232.USD","LU0106261372.USD","LU2746668461.USD","LU0320765646.SGD","LU1244550494.USD","IE00BFXG1179.USD","LU0345770993.USD","IE00BLSP4239.USD","LU1551013342.USD","LU0976567544.SGD","LU0211328371.USD","LU0889565916.HKD","LU1244550221.USD","LU1548497426.USD","IE00BKDWB100.SGD","LU0942090050.USD","LU0208291251.USD","IE00B2B36J28.USD","LU0211326839.USD","LU1668664300.SGD","LU2505996509.AUD","TNGX","LU0211326755.USD","LU0859254822.USD","RVMD","IE00BWXC8680.SGD","JPMO","LU0689472784.USD","IE00BYXW3230.USD","IE0009355771.USD","IE00BJTD4V19.USD","IDYA","LU1670627923.USD","LU1116320901.HKD","LU2430703178.SGD","BK4585","BK4550","IE00B4R5TH58.HKD","LU0211327993.USD","LU2381873111.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642779465","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Dexcom (DXCM), Revolution Medicines (RVMD) and Incyte (INCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642779465","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642779465?lang=en_us&edition=fundamental","pubTime":"2026-06-09 17:10","pubTimestamp":1780996253,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Dexcom (DXCM), Revolution Medicines (RVMD) and Incyte (INCY). Rev...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-dexcom-dxcm-revolution-medicines-rvmd-and-incyte-incy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-dexcom-dxcm-revolution-medicines-rvmd-and-incyte-incy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4504","LU0109394709.USD","LU2125909247.SGD","LU2211815571.USD","LU2210149790.SGD","LU2433249047.HKD","LU0354030438.USD","XBI","LU0128526141.USD","IE00BMPRXN33.USD","IE00B4R5TH58.HKD","BK4551","BK4139","LU1323610961.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE00BMPRXR70.SGD","DXCM","LU1923622614.USD","BK4550","BK4581","LU2125909593.SGD","LU2095319765.USD","BK4532","BK4588","BK4082","BK4585","IE0009355771.USD","BK4137","LU0029874061.USD","XLV","LU0354030511.USD","IE00BJT1NW94.SGD","LU0889565916.HKD","LU2210150020.SGD","LU0320765992.SGD","IE00BFTCPJ56.SGD","HCSG","INCY","BK4534","RVMD","LABU","IE0002141913.USD","LU0266013472.USD","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642643373","title":"Tango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer Treatment -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2642643373","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642643373?lang=en_us&edition=fundamental","pubTime":"2026-06-09 00:28","pubTimestamp":1780936080,"startTime":"0","endTime":"0","summary":"Shares of Tango Therapeutics surged toward a record closing high on Monday after the cancer biotech company announced positive initial data from an ongoing study of treatments for pancreatic ductal adenocarcinoma, the most common and aggressive form of pancreatic cancer.Tango Therapeutics stock soared 42% to $28.74 on Monday, part of a 217% advance this year. Over the past 12 months, the biotech stock has skyrocketed 574%.The Boston-based clinical-stage biotech company Monday released initial data from its ongoing Phase 1/2 study of its cancer drug vopimetostat in combination with the company Revolution Medicines' zoldonrasib or daraxonrasib for patients with advanced MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma, or non-small cell lung cancer.The results showed that a combination of vopimetostat and daraxonrasib produced a 92% objective response rate in pancreatic cancer patients, with a 90% six-month progression-free survival rate and 100% disease control. T","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU0889565916.HKD","BK4007","BK4539","IE00B2B36J28.USD","TNGX","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU0109394709.USD","LENZ","LU0320765992.SGD","BK4139","RVMD","IE0002141913.USD","IE0009355771.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641874274","title":"RBC Capital says Tango-Revolution data strengthens daraxonrasib’s PDAC position","url":"https://stock-news.laohu8.com/highlight/detail?id=2641874274","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641874274?lang=en_us&edition=fundamental","pubTime":"2026-06-08 21:50","pubTimestamp":1780926625,"startTime":"0","endTime":"0","summary":"RBC Capital notes that Tango Therapeutics (TNGX) announced data from the combo of their PRMT5 inhibitor vopimetostat and Revolution Medicines’ (RVM...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rbc-capital-says-tango-revolution-data-strengthens-daraxonrasibs-pdac-position-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rbc-capital-says-tango-revolution-data-strengthens-daraxonrasibs-pdac-position-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD","IE00B4R5TH58.HKD","TNGX","LU0889565916.HKD","LU0708994859.HKD","IE0009355771.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4207","LU0310800379.SGD","LU1267930573.SGD","LU0029864427.USD","IE0002141913.USD","BK4139","LU0320765992.SGD","LU0109394709.USD","IE00B2B36J28.USD","LU0128525929.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641480853","title":"Why Revolution Medicines (RVMD) Is Down 8.8% After Phase 3 Daraxonrasib Pancreatic Cancer Survival Data Release And What's Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2641480853","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641480853?lang=en_us&edition=fundamental","pubTime":"2026-06-08 21:22","pubTimestamp":1780924921,"startTime":"0","endTime":"0","summary":"In late May 2026, Revolution Medicines reported detailed Phase 3 RASolute 302 data showing its oral RAS(ON) inhibitor daraxonrasib achieved statistically significant overall and progression-free survival benefits over standard chemotherapy in previously treated metastatic pancreatic cancer, with a manageable safety profile.\nThe results, presented at ASCO 2026 and published in The New England Journal of Medicine, position daraxonrasib as a potential first-in-class option for RAS-driven...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/why-revolution-medicines-rvmd-is-down-88-after-phase-3-darax","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/why-revolution-medicines-rvmd-is-down-88-after-phase-3-darax","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1854103824.USD","IE00BJT1NW94.SGD","IE00BFMHRM44.USD","LU2357305700.SGD","ON","LU0124384867.USD","IE00BFTCPJ56.SGD","LU1861219969.SGD","LU1861214812.USD","LU1978683503.SGD","LU1861215975.USD","LU0348723411.USD","LU1548497426.USD","IE00BD6J9T35.USD","LU2360107325.USD","LU0889565916.HKD","BK4141","LU1861220033.SGD","BK4585","BK4588","LU0724618433.USD","LU0320765992.SGD","BK4605","LU2298322129.HKD","LU0109394709.USD","IE0002141913.USD","RVMD","IE00BZ199S13.USD","LU1854104046.USD","IE00BJJMRZ35.SGD","BK4512","IE0009355771.USD","IE00B4R5TH58.HKD","LU1720051017.SGD","LU1720051108.HKD","IE00B2B36J28.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revmed.com;ir.revmed.com","stockEarnings":[{"period":"1week","weight":0.0826},{"period":"1month","weight":0.1184},{"period":"3month","weight":0.7978},{"period":"6month","weight":1.0878},{"period":"1year","weight":3.2335},{"period":"ytd","weight":1.1282}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0162},{"period":"3month","weight":0.1169},{"period":"6month","weight":0.0626},{"period":"1year","weight":0.2223},{"period":"ytd","weight":0.0758}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.034782},{"month":2,"riseRate":0.666667,"avgChangeRate":0.00452},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.031822},{"month":4,"riseRate":0.714286,"avgChangeRate":0.114077},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.015463},{"month":6,"riseRate":0.857143,"avgChangeRate":0.047478},{"month":7,"riseRate":0.5,"avgChangeRate":-0.000709},{"month":8,"riseRate":0.666667,"avgChangeRate":0.059948},{"month":9,"riseRate":0.5,"avgChangeRate":0.038151},{"month":10,"riseRate":0.666667,"avgChangeRate":0.019949},{"month":11,"riseRate":0.833333,"avgChangeRate":0.188424},{"month":12,"riseRate":0.5,"avgChangeRate":-0.027192}],"exchange":"NASDAQ","name":"Revolution Medicines, Inc.","nameEN":"Revolution Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Revolution Medicines, Inc.(RVMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Revolution Medicines, Inc.,RVMD,Revolution Medicines, Inc.股票,Revolution Medicines, Inc.股票老虎,Revolution Medicines, Inc.股票老虎国际,Revolution Medicines, Inc.行情,Revolution Medicines, Inc.股票行情,Revolution Medicines, Inc.股价,Revolution Medicines, Inc.股市,Revolution Medicines, Inc.股票价格,Revolution Medicines, Inc.股票交易,Revolution Medicines, Inc.股票购买,Revolution Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Revolution Medicines, Inc.(RVMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}